Skip to main content
PZ Cormay S.A. logo

PZ Cormay S.A. — Investor Relations & Filings

Ticker · CRM ISIN · PLCMRAY00029 LEI · 2594006HZJ8OSNK56U87 WAR Manufacturing
Open in API
Filings indexed 692 across all filing types
Latest filing 2017-08-31 Interim / Quarterly Rep…
Country PL Poland
Listing WAR CRM

About PZ Cormay S.A.

https://cormaydiagnostics.com/

PZ Cormay S.A. is a manufacturer and distributor of in-vitro diagnostic (IVD) solutions for medical laboratories and clinics. The company develops, produces, and sells a comprehensive portfolio of diagnostic reagents, laboratory analyzers, and quality control systems. Its offerings cater to key diagnostic areas, including clinical chemistry, hematology, and immunoassay. Key product lines feature the Accent series of chemistry analyzers, the Auryx immunoassay system, and the Mythic family of hematology analyzers. The company integrates its extensive experience in reagent manufacturing with advanced Swiss hematology technology to provide reliable, high-performance, and cost-effective diagnostic tools to a global network of distributors and healthcare professionals.

Recent filings

Filing Released Lang Actions
1.List_do_Akcjonariuszy_1H_2017.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a letter from the CEO of PZ Cormay S.A. presenting the financial results for the first half of 2017. It contains specific financial data (consolidated revenue, EBITDA, net loss) and discusses business performance, strategic projects (Equisse, Hermes), and corporate restructuring. Since it provides substantive financial data and analysis for a period shorter than a full fiscal year, it qualifies as an Interim/Quarterly Report (IR). H1 2017
2017-08-31 Polish
Status projektów Equisse, Hermes Senior – aktualizacja informacji - Content (PL)
Earnings Release Classification · 99% confidence The document is a formal communication from the Management Board ("Zarząd") of PZ Cormay S.A. It provides an update on the progress of two key development projects (Equisse and Hermes Senior analyzers), referencing previous periodic reports (quarterly report for Q1 2017) and ongoing activities like regulatory submissions (URPL, SwissMedic), internal validation, and planning for external validation and commercial launch timelines (Q4 2017, Q3 2017). This detailed explanation of business trends, project status, and outlook, issued by management, aligns perfectly with the definition of Management Reports (MDA). Although it mentions future periodic reports, the core content is the management's explanation of current operational status, not just an announcement of a report's publication (RPA) or a general regulatory filing (RNS). Q1 2017
2017-07-31 Polish
Ustalenie ceny emisyjnej akcji serii L - Content (PL)
Capital/Financing Update Classification · 98% confidence The document text, written in Polish, discusses the Management Board (Zarząd) setting the issue price (cena emisyjna) for a new series of shares (akcji serii L) following an authorization from an Extraordinary General Meeting (Nadzwyczajnego Walnego Zgromadzenia). This action directly relates to raising capital through the issuance of new shares, which falls under the definition of Capital/Financing Update (CAP). Although it involves share issuance, the core focus is the setting of the price for a capital increase, making CAP more specific than SHA (Share Issue/Capital Change) or POS (Transaction in Own Shares). The document explicitly references MAR Regulation (Rozporządzenia MAR), indicating a formal regulatory disclosure regarding a financing event.
2017-07-26 Polish
Zatwierdzenie Prospektu Emisyjnego - Content (PL)
Capital/Financing Update Classification · 95% confidence The document text is a formal announcement from the Management Board of PZ Cormay S.A. (Emitent) regarding the approval of the Issuance Prospectus (Prospekt Emisyjny) by the Polish Financial Supervision Authority (KNF). The prospectus relates to a public offering of Series L shares and the subsequent acquisition of shares in Orphée SA. Crucially, the text states: 'Zarząd jednocześnie informuje, iż publikacja Prospektu Emisyjnego planowana jest na dzień 24 lipca 2017 roku' (The Management Board also informs that the publication of the Issuance Prospectus is planned for July 24, 2017). Since this document is an announcement about the upcoming publication of a major financial/capital document (the Prospectus), and given its short length (1251 chars), it fits the definition of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). A Prospectus itself is a type of financing document. Since 'Capital/Financing Update' (CAP) covers fundraising and financing activities, and this announcement directly relates to the public offering and prospectus, CAP is the most specific fit, as the core subject is the capital raising event itself, not just the announcement of a report's availability (RPA/RNS). However, the document explicitly announces the *publication* of the Prospectus, which strongly suggests RPA based on the 'MENU VS MEAL' rule if the Prospectus itself is the primary document. Given the content is entirely about the terms of the offering and the prospectus publication schedule, CAP (Capital/Financing Update) is the most accurate thematic classification for the underlying event being announced, even if RPA is technically correct for the announcement format. I will prioritize the subject matter (financing/offering) over the announcement format, leaning towards CAP.
2017-07-20 Polish
Analizator biochemiczny Equisse – aktualizacja statusu projektu - Content (PL)
Regulatory Filings Classification · 99% confidence The document is a short announcement from the Management Board of PZ Cormay S.A. (Spółka) referencing previous reports and informing that a deadline for regulatory review (URPL in Poland) for a biochemical analyzer (Equisse) has passed without objection. Consequently, the company can now begin commercialization in Poland and Europe. This announcement details a significant business development and regulatory milestone that impacts future operations and financial outlook, but it is not a full financial report (like 10-K or IR), an earnings release (ER), or a management discussion (MDA). It is a specific update on a strategic project's regulatory clearance, which fits best under general Regulatory Filings (RNS) as a specific event announcement, or potentially a Capital/Financing Update (CAP) if the commercialization was tied to funding, but RNS is the most appropriate general regulatory announcement category for this type of procedural update that doesn't fit other specific categories like DIRS, DIV, or M&A.
2017-07-17 Polish
Zgłoszenie analizatora biochemicznego Equisse. - Content (PL)
Regulatory Filings Classification · 99% confidence The document is a short announcement (1004 characters) from the Management Board ('Zarząd') of PZ Cormay S.A. It references previous reports and announces a specific action taken on June 30, 2017: the submission of the Equisse biochemical analyzer to the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL). The text focuses on a regulatory submission process that will allow the company to commercialize the device, which is deemed strategically important. This is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). It is a specific regulatory/product update. Given the nature of announcing a submission to a regulatory body concerning a product, it fits best under general Regulatory Filings (RNS) as a specific, non-standard announcement, or potentially a Legal Proceedings Report (LTR) if it were about a dispute, but here it is about product clearance. Since it is a specific regulatory action announcement that doesn't fit the other specific categories like DIRS, DIV, or CAP, RNS (Regulatory Filings / Miscellaneous) is the most appropriate fallback, although it details a significant operational/regulatory step.
2017-06-30 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.